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Abstract
Background: Pathogen-specific metabolic pathways may be detected by breath tests based on introduction of stable
isotopically-labeled substrates and detection of labeled products in exhaled breath using portable infrared spectrometers.
Methodology/Principal Findings: We tested whether mycobacterial urease activity could be utilized in such a breath test
format as the basis of a novel biomarker and diagnostic for pulmonary TB. Sensitized New-Zealand White Rabbits
underwent bronchoscopic infection with either Mycobacterium bovis or Mycobacterium tuberculosis. Rabbits were treated
with 25 mg/kg of isoniazid (INH) approximately 2 months after infection when significant cavitary lung pathology was
present. [
13C] urea was instilled directly into the lungs of intubated rabbits at selected time points, exhaled air samples
analyzed, and the kinetics of d
13CO2 formation were determined. Samples obtained prior to inoculation served as control
samples for background
13CO2 conversion in the rabbit model.
13CO2, from metabolic conversion of [
13C]-urea by
mycobacterial urease activity, was readily detectable in the exhaled breath of infected rabbits within 15 minutes of
administration. Analyses showed a rapid increase in the rate of
13CO2 formation both early in disease and prior to treatment
with INH. Following INH treatment, all evaluable rabbits showed a decrease in the rate of
13CO2 formation.
Conclusions/Significance: Urea breath testing may provide a useful diagnostic and biomarker assay for tuberculosis and for
treatment response. Future work will test specificity for M. tuberculosis using lung-targeted dry powder inhalation
formulations, combined with co-administering oral urease inhibitors together with a saturating oral dose of unlabeled urea,
which would prevent the d
13CO2 signal from urease-positive gastrointestinal organisms.
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Introduction
After a long hiatus in the development of new drugs for the
treatment of tuberculosis (TB), exciting compounds such as
TMC207/ R207910, PA824 and OPC6768 are coming out of
preclinical stages and entering into clinical trials, with the promise
of other new compounds to follow [1–3]. However, it has become
clear that there is a critical need for new biomarkers of the
response of TB to drug therapy, that can provide surrogates of
drug efficacy to guide design and conduct of these clinical trials
[4–6]. Without such biomarkers, these trials could be longer, more
complicated and costlier, thereby delaying the availability of new
drugs and perhaps even discouraging trials of others. Surrogate
biomarkers are especially important in Phase IIa/b design, where
issues such as drug doses and regimen design are often complex,
although they would be useful throughout a trial, and beyond into
treatment monitoring.
The need for these new biomarkers derives from inadequacies in
current endpoints. In particular, the current standard, of relapse-
free survival for 2 years after treatment, makes trials long and
unwieldy, although a well-justified earlier biomarker(s) might be
acceptable to regulatory agencies in certain circumstances. Ideal
biomarkers would be rapid and easy to use even in relatively low
resource settings, and administered and read in point-of-care
manner. To be useful in the design and implementation of drug
trials, it should allow sensitive and dynamic monitoring of
mycobacterial burden treatment throughout much (if not all) of a
treatment regimen in a wide range of patient populations, providing
a surrogate for the process of whole organ homogenization and
determination of colony forming units (CFU) that can only be
obtained in preclinical animal studies [4]. The three current
biomarkers available, sputum smear positivity, early bactericidal
activity (EBA) or conversion to negative sputum culture at two
months, do not fulfill these requirements although they continue to
be useful, with the later also accepted as a biomarker of sterilizing
activity. Although immune-based surrogates are invaluable in
diagnosis, there are concerns about their usefulness to dynamically
observe the effects of therapy upon bacterial load, and also about
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Furthermore, the variance in host response and uncertainties in
the relationship between CFU and biomarker response, mean that
these approaches are unlikely to provide the required information.
Pathogen-specific metabolic pathways may be rapidly detected by
breath tests based on introduction of nontoxic isotopically-labeled
substrates and detection of labeled products that are specific to
microbial metabolism in exhaled breath. Detection of
13CO2 in
exhaled breath isparticularlyattractivebecause theratioof
13CO2to
12CO2 may be readily measured using either mass spectrometry, or
by portable infrared spectrometers. This approach has been
employed to diagnose Helicobacter pylori infection and to monitor of
its eradication by drug treatment [7] using bacterial urease as a
biomarker, with isotope breath testing based upon giving patient an
isotopicallylabeled ureadrink andmonitoring exhaled labeled CO2.
The entire diagnostic process can be completed within about
15 minutes (for example using the Breathtek
TM test from Otsuka)
using a portableinfrared detection device and stable tracer packages.
M. tuberculosis also possesses an active urease, used in classical
microbiological assays [8–12], and also a potential virulence factor
that enhances intracellular survival by alkalinizing the microenvi-
ronment and preventing phagosome-lysosome fusion [13–15].
We hypothesized that an approach based upon monitoring
specific mycobacterial metabolic conversion of stable-isotope-
labeled substrate into labeled exhaled gas, analogous to the widely-
accepted breath test for Helicobacter pylori, together with lung
delivery of the labeled substrate, would allow the detection of M.
tuberculosis within the lung without having to obtain sputum or
other samples that may only partially report upon the total lung.
Furthermore, we hypothesized that the extent of conversion of the
labeled-substrate to labeled gases is dependent upon bacterial
density, and so this test could report upon total bacterial load and
its response to therapy, and so provide a useful biomarker. Finally,
if a biomarkers predictive ability is shown in clinical trials of new
drugs, it could then be used for rapid point of care monitoring, and
guide treatment of TB cases, especially MDR/XDR for which the
increased monitoring costs would be justified by improved
treatment outcomes with fewer failures [16,17].
In order to test our hypothesis, we used an animal model that
utilizes presensitization and bronchoscopic inoculation to reliably
produce pulmonary cavities in the rabbit model of tuberculosis
[18]. Because this model achieves bacillary burdens that are
comparable to those observed in humans with advanced
pulmonary TB, it mirrors levels of mycobacterial urease in
patients with TB. To drive lung specificity, the tracer, a
13C-urea
solution was directly instilled in the airways of infected animals at
various time points during infection. This models pattern of tracer
distribution we would obtain using a dry powder inhalation dose
delivery system, which would be the preferred ultimate embodi-
ment for human treatment we plan. Exhaled breath specimens
were collected and the
13CO2/
12CO2 ratio was quantified by
isotope ratio mass spectrometry over a selected interval.
Approximately 8 weeks after infection, isoniazid (INH) was given
daily for a 14-day interval. Breath testing was obtained at multiple
time points both during and after treatment to determine if
mycobacterial urease activity could be utilized as a rapid
biomarker for pulmonary TB and its response to therapy.
Methods
Ethics Statement
All animals were maintained under protocol ID number
RBO8M512 which is approved by the Institutional Animal Care
and Use Committee of Johns Hopkins University.
Microorganisms
Cultures were prepared by thawing frozen stock aliquots of
Mycobacterium bovis (M. bovis) Ravenel and M. tuberculosis (M. tb.)
H37Rv. Mycobacteria were grown in 7H9 Middlebrook liquid
medium supplemented with oleic acid, albumin, dextrose and
catalase (Becton Dickinson, Inc., Sparks, MD), 0.5% glycerol and
0.05% Tween 80.
Urease activity
Cultures of M. tb. CDC 1551, M. bovis BCG, and two urease
deficient mutants (M. tb. CDC 1551 DureB and DureD) were
cultivated in 7H9 Middlebrook liquid medium and diluted to 10
3
CFU/mL to test media specifications. Urease activity was
measured using BD BBL
TM Taxo
TM Differentiation Disc Urea
Kit (Becton Dickinson, Inc., Sparks, MD) Colorimetric changes
were monitored after one day and three days post- urea disc
introduction. Optical density measurements were undertaken at
an OD550nm after 3 days of incubation with the urea discs.
Specificity of urease activity was normalized to the CFU count at
the time of optical density calculations (Figure S1).
Animals
6 pathogen-free outbred New Zealand White rabbits (2.5–3.5kg)
were obtained from Covance Research Products, Inc. (Denver,
PA). Animals were housed in biosafety level 3 conditions in
standard cages. All rabbits were sensitized every 3–4 days by
administration of five subcutaneous injections of 10
7 heat-killed M.
bovis in incomplete Freund’s adjuvant. Successful acquisition of
delayed type hypersensitivity (DTH) reaction was undertaken 25
days after the last sensitization injection by the intradermal
injection of 0.1 cc of old tuberculin (Synbiotics Corp, Kansas City,
MO). The tuberculin reaction was read 48–72 hours later and skin
fold thickness was measured in two dimensions. Results were
calculated using the formula for the volume of an oval spheroid.
Infection and Clinical Assessment
Animals were sedated with ketamine (15–25 mg/kg) and
xylazine (5–10 mg/kg). Reversal of sedation was achieved with
yohimbine (0.1–0.2mg/kg). Infection was administered by instil-
lation of a liquid inoculums through a 3.0mm flexible broncho-
scope Pentax FB-8V pediatric bronchoscope (Pentax Medical
Company, Montvale, NJ) into the subsegmental bronchi of the
right middle lobe. A bacillary suspension of 0.3cc containing 10
3–
10
4 CFU was delivered through the insertion port of the
bronchoscope. Confirmation of the amount of CFU delivered
was performed by plating serial dilutions of the inoculated
suspension – as described above. After infection, animals were
monitored twice weekly for clinical appearance, rectal temperature
and weight.
Antimicrobials
Isoniazid (INH) was obtained and formulated for intramuscular
(IM) administration. 25mg/kg of INH was administered IM daily
for 2 weeks approximately eight weeks after bronchoscopic
infection.
Urea Breath Sampling
A suspension of 40–50mg of
13[C] labeled urea (100 mg/mL)
was instilled via a small bore feeding tube introduced through a
4.0mm endotracheal tube. The feeding tube was advanced to be at
the level of the carina or slightly beyond the orifice of the right
mainstem bronchus. After instillation of the urea, the animals were
held supine with 45 degree head elevation to enhance distribution
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10 minutes and 20 minutes) after isotopic urea instillation, a 14-
French feeding tube was then introduced through the endotra-
cheal tube to the level of the carina. A 10cc syringe attached to the
feeding tube sampled air with occasional forced expiratory
maneuvers being undertaken (i.e. gentle squeezing of the rib
cage). Sampled air was then inserted through a 0.35micron filter
into a 6.0mL red-top Vacutainer (Becton Dickinson, Franklin
Lakes, NJ, USA). These air sampling procedures were undertaken
prior to bacillary infection and selected time points post-infection.
At each time point, baseline samples of environmental air with
ambient
13CO2 and
12CO2 were obtained.
Measurement of
13CO2 Conversion
3 ml of 0.2 micron filtered exhaled breath sample was
transferred into a 10ml septa-sealed vial containing helium gas,
and analyzed by gas isotope ratio mass spectrometry using a
Delta
plusXL instrument for
13C enrichment in headspace CO2.
The
13C enrichment in CO2 (d
13CO2) is reported is in the delta
notation, where the delta value is given in % as follows:
d~
Rx{Rstd
Rstd

x1000
where R is the ratio of the abundance of the heavy to light isotope,
x denotes the sample, and std is an abbreviation for standard,
Vienna Pee Dee Belemnite (VPDB). Reproducibility in d
13C was
better than 0.1%. The values of d
13CO2 were found to increase
linearly with time after urea administration, and so these values
were fitted linearly, and the increase in d
13CO2 per minute
evaluated.
Necropsy
Rabbits were observed for a minimum of 50 days after infection.
Euthanasia was performed if animals displayed any signs of
respiratory distress and/or significant loss of weight (greater than
200g). Rabbits were euthanized with intravenous euthasol (Virbac
Corporation, Fort Worth, TX). Specimens were obtains from the
lungs and extrapulmonary locations. Cavity specimens, where
applicable, represented the lumen contents, wall and surrounding
inflammatory tissue. Extrapulmonary sites included the spleen,
liver, kidney (bilateral), urine, feces, Peyer’s patches in the small
intestine.
Scoring of gross pathology and cavity histopathology
Grossly visible pulmonary primary lesions in the right lower lobe
and secondary lesions in the ipsilateral & contralateral lungs were
scored according to their prevalence. Grossly visible extrapulmo-
nary lesions were scored according to their prevalence and location.
Tissue sections were embedded with paraffin and stained with
hematoxylin and eosin. All slides were examined with a Nikon
Microscope Eclipse E800 (Nikon Instruments Inc., Melville, NY).
Scoring of bacterial CFU counts
CFU counts were measured at all predetermined pulmonary
and extrapulmonary locations from each infected rabbit. Tissue
samples from each site were homogenized and plated on selective
7H11 agar as described above. Enumeration of CFU counts
occurred on days 14, 21 and 28.
Statistics
SigmaStat 3.0 was used to determine statistical values, using
Anova and t-test, a p value of 0.05 or less indicating significance
Results
In vitro studies
The linearity of a potential biomarker with CFU count is
important, and so M. bovis BCG, a vaccine strain of M. tuberculosis
was incubated with
13C-labeled urea and headspace gas analyzed
after 30 minutes for d
13CO2 (the enrichment of headspace CO2
with
13CO2) and results of a typical experiment shown in Figure 1.
It can be seen that d
13CO2 increased in a linear manner with CFU
over more than 2 orders of magnitude, and that the slopes (extent
of conversion per 10
6 CFU) for different experiments were similar
(data not shown). Importantly, detection was possible at levels of
10
4 CFU ml
21, significantly lower than most observed levels in
sputum, which are observed in the range of 10
6 to 10
8 CFU ml
21
in EBA studies so that there is the potential for great sensitivity
(17).
Varying lung pathology following presensitization and
bronchoscopic infection
Each rabbit was effectively sensitized with heat-killed M. bovis
and all converted their tuberculin skin tests to positive prior to
infection similarly to previous work (Table 1) (18). Even Rabbit
B1, which showed the least amount of skin test reactivity,
successfully generated a lung cavity. Varying gross pathology
had been noted utilizing direct bronchoscopic infection into the
right middle lobe (Figure 2). Both rabbits T1 and T2 infected with
M. tuberculosis H37Rv did not develop full cavitary lesions. Rabbit
T1 developed diffuse granulomatous disease that was most
prominent in the initial site of infection in the right middle lobe.
No signs of liquefaction or caseation were appreciated on
dissection of the right middle and lower lobes. CFU counts from
rabbit T1 yielded over 10
6 bacilli from the right lung and slightly
greater than 1.5 log from the contralateral side (Table S1). Rabbit
T2 displayed minimal granulomatous disease with focal areas of
necrosis. Necropsy of the rabbit was complicated by diffuse
pulmonary hemorrhage after intubation. The lungs were grossly
engorged with multiple clots appreciated in the bilateral lung
vasculature. No observable CFUs were noted from plating various
specimens from bilateral lung sections from rabbit T2.
Figure 1. Mycobacterial urease assay by conversion of [
13C]
urea to
13CO2 reports upon CFU over a wide range. M. bovis BCG
was incubated for 30 minutes with 5 mg ml
21 [
13C]-urea and
headspace gas sampled and analysed for
13CO2 enrichment (reported
as d
13CO2).
doi:10.1371/journal.pone.0012451.g001
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formed cavitary lesions with the exception of rabbit B4 (Figure 2).
The highest total CFU counts were measured in the inner cavitary
contents of B1 and B3, which yielded over 10
8 bacilli (Figure S2).
Rabbit B2 contained approximately 0.3 log unit more CFUs in the
right lung as compared to liquid caseum. Contralateral dissem-
ination to the left lung was noted in all cavitary rabbits. Rabbit B4
developed no cavitary lesion but notable granulumatous disease
isolated to the bilateral upper lobes was appreciated. Specimens
from bilateral sections yielded CFU only from the right lung.
Thus, the animals displayed a range of pathologies, and thus their
use represented a realistic test of potential success of the approach
in a similar human population.
Bacterial correlates of disease phenotype:
extrapulmonary dissemination of M. bovis but not
M. tuberculosis
In contrast to M. tuberculosis infections, M. bovis-infected rabbits
uniquely showed bacterial dissemination to extrapulmonary organs
which was consistent with our previous lung cavitation studies (Figure
S3). Rabbits B1 and B3 had notable splenic CFU counts. Greater than
2.5 log units of kidney CFU counts were seen in all M. bovis-infected
rabbits with the exception of B1. The kidney CFU counts were
approximately 1 log greater than in the spleen. Grossly visible
granulomas were noted on the surface of these kidneys. Extrapulmo-
nary dissemination of M. tuberculosis was not observed on gross
pathology or microbiologic assessment. Both the M. tuberculosis H37Rv
strain and the M. bovis Ravenel strain were tested for urease activity by
the urea disk assay and were found to be strongly positive (Figure S1).
Diagnostic utility of urea breath testing in tuberculous
rabbits
All rabbits had urea breath testing performed prior to
bronchoscopic infection, and some detectable enzymatic conver-
sion of [
13C]-urea was noted at baseline. The increase in d
13CO2
after urea administration was observed to follow approximately
linear kinetics over 20 minutes (typical example of a post infection
case in Figure 3 and so these were fitted to provide the rate of
increase in d
13CO2 minute
21.The d
13CO2 minute
21 conversion
rate ranged from 0.1 to 0.2 [per mil units/minute] (Figure 4).
Increasing UBT signals were observed in all evaluable rabbits
(with presumed lower CFU count), during the range of days that
breath testing was initially undertaken after infection, 42–62 days
(Figure 4). All conversion rates were greater than 0.2 [per mil
units/minute] post-infection. The rabbits with the most prominent
lung pathology showed the greatest detectable d
13CO2 signal.
Rabbit B4 had the least amount of grossly observable pathology on
necropsy (bilateral upper lobe granulomas) and the lowest
conversion rate. Rabbit B4 had approximately 3 log CFU/ml
appreciable in the right lung and may serve as the possible basis of
the lower CFU limit of detection (Figure 2). Rabbit T1, with
numerous bilateral granulomas and no cavitary disease on
necropsy, had the highest detectable d
13CO2 post-infection.
Urea breath testing as a treatment response marker in
tuberculous rabbits
INH (25mg/kg) was provided daily for a 14-day interval to all
rabbits but B1. Rabbit B1 was euthanized prior to treatment due
to significant respiratory distress observed prior to the treatment
time period. [
13C]-urea conversion rates were tested during
treatment for all rabbits with the exception of B1 and B2
(Table 1). During and/or within 2 weeks post-treatment, a
decrease in labeled urea conversion was appreciated in all tested
animals. Rabbit T1 had the steepest decline in detectable d
13CO2.
After 2 weeks post-treatment, a rise in d
13CO2 was noted in
rabbit T2. Though no observable CFU counts were noted on
necropsy, minimal gross pathology was appreciated. This
continued rise in urease activity was noted after 8 weeks post-
infection in rabbit T2. It Rabbits B3 and B4 had a notable decline
in the conversion rate after 2 weeks post-INH treatment. Rabbit
B3 showed a detectable d
13CO2 after 4 weeks post-treatment likely
due to the high bacillary burden in the developed lung cavity.
Rabbit B4 demonstrated solely upper lung lesions and a continued
decline in the conversion rate was appreciated 4 weeks after
treatment cessation. Rabbit B2 did not undergo urease detection 2
weeks post-treatment. However, testing performed 4 weeks post-
treatment yielded a continued elevation in detectable d
13CO2.
The continued rise in urease conversion in rabbit B2, as in rabbit
B3, may be attributable to the formation of a significant cavitary
lesion with a high bacillary burden (Figure 2). Only rabbit T2 had
Table 1. Disease parameters associated with rabbit infection.
Rabbit Skin Reaction (mm
3)
{ Days of Infection Time Points (days) Breath Testing Obtained1
T1* 1703 96 Day 0 (pre-infection), Day 54 (pre-treatment), Day 63 (0 days post-
treatment)
T2* 2159 126 Day 0 (pre-infection), Day 62 (pre-treatment), Day 69 (7 days into
treatment), Day 104 (33 days post-treatment), Day 115 (44 days
post-treatment), Day 127 (56 days post-treatment)
B1
{ 3250 50 Day 0 (pre-infection), Day 44 (pre-treatment)
B2
{ 937 93 Day 0 (pre-infection), Day 47 (pre-treatment)
B3
{ 1524 92 Day 0 (pre-infection), Day 49 (pre-treatment), Day 63 (10 days into
treatment), Day 89 (19 days post-treatment)
B4
{ 1434 90 Day 0 (pre-infection), Day 42 (pre-treatment)
Day 89 (19 days post-treatment)
*M. tuberculosis H37Rv.
{M. bovis Ravenel.
{Skin reaction was measured as cutaneous reactivity to Old Tuberculin 25 days after the last pre-sensitization. The tuberculin reaction was read 48–72 hours after
subcutaneous injection of Old Tuberculin to confirm successful acquisition of DTH immunity.
1Exhaled air samples were extracted at varying frequencies both prior and after treatment with INH (25mg/kg). Treatment was provided daily over a 14 day time interval.
Select rabbits were administered breath testing at multiple time points during infection and after treatment.
doi:10.1371/journal.pone.0012451.t001
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animals noted post-infection demonstrated a significant increase in
the mean d
13CO2 conversion rate (Figure 5), that was significantly
decreased after treatment.
Discussion
The results of this study suggest that delivery of [
13C]-urea into
the lungs of rabbits infected with urease-producing mycobacteria
could be used as a diagnostic modality to estimate lung burdens of
disease and their response to therapy. Both M. tuberculosis and M.
bovis infected rabbits have a significant rise in the rate of d
13CO2
formation prior to treatment that was decreased after INH
therapy. Although the rise in urea conversion was most
prominently observed in rabbits with cavitary or diffuse lung
pathology, it was notable even in rabbits with the greatest amount
of localized disease (infection in the right middle lobe as evident in
rabbits T1 and T2) so that the approach would seem applicable
Figure 2. Gross pathology of selected lung specimens at necropsy. (A) M. tuberculosis H37Rv T1. (B) M. tuberculosis H37Rv T2. (C) M. bovis B1.
(D) M. bovis B2. (E) M. bovis B3. (F) M. bovis B4.
doi:10.1371/journal.pone.0012451.g002
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powder inhalers could improve upon this aspect yet further.
Urease is present in most pathogenic mycobacteria, including
M. tuberculosis and M. bovis [19]. The presence of urease in
mycobacteria was first noted by So ¨hngen in 1913 and confirmed
by Corper and Sweany in 1918 [20–22]. The testing was based on
the enzyme’s ability to degrade urea into CO2 and NH3, the latter
of which served as the foundation for bacterial classification. Toda
et al. refined the classification of mycobacteria by urease activity
through the development of a rapid colorimetric broth technique
[8]. This was followed years later with further development of
rapid urease-based testing that involving urea-embedded test discs
and modified BACTEC radiometric instrumentation [11,12].
Since the last major publications on urease-based diagnostics in
the 1970s, no further work dedicated to this subject matter has
been noted after an extensive review of the literature. Our work
stems from fusing this classical approach of mycobacterial
classification and more recent urease-based testing for the
diagnosis of H. pylori.
Urea breath testing (UBT) for H. pylori involves the oral intake
of [
14C]- or [
13C]-urea and assessing the d
14CO2 or d
13CO2
through exhaled breath specimens. This sensitive diagnostic is now
commonly utilized as a rapid test of H. pylori infection [7,22]. Our
model contains an important modification of H. pylori UBT in that
instead of oral delivery of the labeled urea, we used direct
intrapulmonary administration of the non-radioactive tracer,
delivering the testing agent to the area of interest. No adverse
respiratory events were noted after instillation of the urea
compound. Lung-targeted delivery of the [
13C]-urea via dry
powder inhalers will represent our delivery for future human
studies, in which more efficient diffuse lung deposition of the
testing agent will be required [23].
Our model potentially offers a path toward a novel point-of-care
diagnostic for TB and TB treatment response. Point-of-care
diagnostics are desperately needed in high-burden settings in order
to reduce delays in disease detection and to accelerate the
recognition of treatment failure suggestive of drug-resistant
tuberculosis [24]. Delays in diagnosis, which characterizes several
modern TB diagnostics, may be directly attributable to the
inability to control the epidemic [25–27]. The conversion rate per
minute shows the test may rapidly and reliably detect pulmonary
tuberculosis associated with a variety of pathologic presentations.
The animals in our study displayed not only cavitary lesions, but
also diffuse granulomatous disease and isolated upper lobe
granulomas. Despite the variability in the tissue-based disease,
Figure 3. Exhaled d
13CO2 increased linearly after urea instilla-
tion. Breath samples were obtained prior to, and 1, 5, 10 and
20 minutes after urea instillation. Fig 3 shows typical data from a
heavily infected rabbit.
doi:10.1371/journal.pone.0012451.g003
Figure 4. Conversion rate of [
13C]-urea prior and after treatment with INH. Baseline level of [
13C]-urea conversion was obtained on all
animals prior to bronchoscopic infection. Urea conversion rates were obtained at a single time point after 4–8 weeks post-infection. INH 20mg/kg
daily for a 2-week interval was initiated after 8 weeks from the time of infection. Conversion rates were ascertained either during or within 10 days of
treatment cessation. Urease conversion were lastly determined at single time points after 2–4 weeks and 6–8 post-treatment in selected rabbits.
doi:10.1371/journal.pone.0012451.g004
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13CO2 after infection.
The developed test fulfills the criteria for effective point-of-care
diagnostic which requires an easily instituted, cost-effective and
rapidly applied technology. Isotopic gas ratio analysis may now be
conducted with compact infrared spectrophotometers such as
POCone
TM (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan).
Exhaled air may be simply obtained through one-way valve bags
and analyzed in this device.
Our model also provides a novel biomarker for TB drug therapy
trials. Biomarkers are actively being sought to improve therapeutic
strategies and validate novel TB drug and vaccine candidates
[4,6]. INH was given daily for 2 weeks to 5 rabbits of which 4 had
time points taken after the medication period. All four rabbits had
a decline in their d
13CO2 conversion rate upon testing just prior to
2 weeks post-treatment. Continued decline in conversion rates
were noted in rabbit B4 which demonstrated solely bilateral upper
lobe granulomatous disease. Treatment of such minimal disease
with 2 weeks of INH was demonstrated with the continued decline
in conversion rates. Adaptation of this test to humans might allow
for serial monitoring of a biomarker of lung CFU during treatment
and offer valuable early information on whether bacterial burdens
are responding to antimicrobial therapy. Breath testing may allow
for actionable information within the time frame of minutes to
determine if TB bacilli are sensitive to an employed drug regimen.
As opposed to currently utilized sputum analyses or molecular-
based assays being used for drug susceptibility, urea breath testing
for M. tuberculosis would allow for a rapid acknowledgement of
treatment efficacy and need for treatment modifications for drug-
resistant TB [28,29].
It is worth noting that the approach detailed here has the
potential to be much more rapid and easy to apply than classical
EBA studies to determine the usefulness of a chemotherapeutic
agent, as 3 to 4 weeks cultures for CFU are not required. The
potential also exists to avoid some known drawbacks of EBA- the
need for extensive sputum, collection, the limited sampling of site
of sputum production (as opposed to the entire lung), and the
potential for bacterial and/or fungal contamination of cultures
[30]. EBA studies assess the early phase of TB treatment, in which
a drug’s ability to kill metabolically active bacilli is being evaluated
[31]. However, the assessment of the latter sterilization phase of
treatment has been one of great debate. Extended EBA studies
(days 2 to 14 of treatment) have unfortunately not proven itself as a
significant surrogate marker for the detection of sterilizing activity
[32,33]. Currently, the traditional 2 month culture conversion is
the most commonly utilized method being employed as a marker
of sterilization [34]. Our test successfully detected the bactericidal
activity of INH which was active against the numerous actively
replicating bacilli in our cavitary rabbits over a 14-day time
interval. Future experiments to determine the utility of this
approach would include the use of sterilizing drugs (i.e. rifampin,
pyrazinamide, etc.) over a designated time interval so as to also
determine the value of urea breath testing as a marker of
sterilization activity.
Our study was limited by the possible lack of specificity, the
positive baseline signal, resulting from other urease-producing
microbial species (such as select Pseudomonas, Klebsiella, non-
tuberculous mycobacteria and H. pylori) [35,36]. This organism is
of particular importance for future translational work given that
approximately 50% of the world’s population is infected and the
highest rates are in developing nations [37]. Most Helicobacter
species are rapidly cleared by rifampin treatment and therefore
serial UBT measurements in rifampin-treated patients (such as in
early drug trials in already-treated patients) might not show long-
term false-positivity due to endogenous Helicobacter carriage
[38,39].
However, broader adoption will require solutions to this
potential confounder. It would be possible to combine inhaled
labeled urea in humans (to drive lung specificity of tracer delivery)
with an oral therapy that includes inhibitors of Helicobacter
urease, such as bismuth salts (i.e. Pepto-BismolH) or proton pump
inhibitors or lithostat to suppress GI urease activity and possible
confounding of data [40,41]. An additional approach would be to
co-administer a urea drink (similar to the Breathtek approach for
H. pylori) that is not enriched in
13C, but rather has this at normal
abundance: therefore any CO2 produced by gut organisms would
not be enriched in
13CO2 and thus not confound the signal from
the lungs. Finally, in humans, measurements could be made
rapidly after urea inhalation, before sufficient time for any urea to
reach the gut, converted to CO2 and then exhaled. Such
approaches would be most easily tested and adopted in clinical
trials of new drugs, where support infrastructure and patient
characterization would be much higher than in the field, and
success there would allow for broader adoption.
In summary, this study describes a novel use of [
13C]-urea
breath testing as a diagnostic and treatment biomarker for TB
using lung delivery of tracer. A significant rise in d
13CO2 was
noted after 6 weeks post-infection in all rabbits which displayed
differing pulmonary pathologies. The reversal in the rate of
conversion after two weeks of daily therapy with INH was also
appreciated in selected rabbits within 2 weeks post-treatment. This
experimental approach may have important implications for
future development of point-of-care diagnostics, treatment mon-
itoring, and testing of new TB therapeutics.
Supporting Information
Table S1 Mean log pulmonary, spleen and kidney CFU counts
at necropsy for all rabbits. Multiple samples of the right lung (the
site of infection), left (contralateral) lung, cavity wall, caseous
cavitary material, spleen and kidney tissue were removed from
areas with the greatest discernable gross pathology. The log CFU
count/gram of tissue was determined after tissue homogenization
Figure 5. Mean conversion rates of [
13C]-urea per minute
among M. tuberculosis H37Rv and M. bovis-infected rabbits.
Repeated measurements had occurred of each breath test sample.
Significant conversion rate differences are noted after both infection
and treatment with 25mg/kg of INH. Rates were obtained prior to
infection, 4–8 weeks after bronchoscopic infection and within two
weeks post-INH treatment.
doi:10.1371/journal.pone.0012451.g005
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greatest intrapulmonary and extrapulmonary pathology.
Found at: doi:10.1371/journal.pone.0012451.s001 (0.03 MB
DOC)
Figure S1 Urease activity of select Mycobacterium species. (A)
Differentiation of observed urease activity was undertaken of M.
bovis BCG, M. tb. CDC 1551, and two urease deficient mutants (M.
tb. CDC 1551 DureB and DureD), Colorimetric changes were
visually observed after one and three days post inoculation with a
urea-embedded disc. (B) Optical density measurements were
undertaken after 3 days of incubation with the urea discs and
specificity of urease activity was normalized to CFU counts.
Found at: doi:10.1371/journal.pone.0012451.s002 (0.18 MB TIF)
Figure S2 Mean pulmonary CFU counts at necropsy for
evaluable M. bovis-infected rabbits. Multiple samples of the right
(the site of infection) and left (contralateral) lung tissue were
removed from areas with the greatest discernable gross pathology.
Samples from the cavity wall and luminal caseous contents
material were also obtained. The log CFU count/gram of tissue
was determined after tissue homogenization and plating dilutions.
The graph displays solely evaluable rabbits with detectable CFUs
in all lung tissues. Additional information is in Table S1.
Found at: doi:10.1371/journal.pone.0012451.s003 (0.07 MB TIF)
Figure S3 Mean spleen and kidney CFU counts at necropsy.
Multiple samples of kidneys and spleens were removed from tissues
with the greatest discernable gross pathology. The log CFU
count/gram of tissue was determined after tissue homogenization
and plating dilutions. Additional information is in Table S1. As
noted in previous published experiments, M. tuberculosis H37Rv
demonstrated no evidence of extrapulmonary dissemination as
compared to M. bovis
24.
Found at: doi:10.1371/journal.pone.0012451.s004 (0.05 MB TIF)
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